Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme by Hsieh, Cheng-Ta & Ju, Da-Tong
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter
Stereotactic Radiosurgery for
Recurrent Glioblastoma
Multiforme
Cheng-Ta Hsieh and Da-Tong Ju
Abstract
Glioblastoma multiforme (GBM) is the most aggressive intracranial tumor that
primarily affects adults. Since the introduction of temozolomide in 2005, maximal
resection surgery with concurrent chemoradiation has become the standard treat-
ment method for patients with newly diagnosed GBM. Although newly discovered
chemoagents have been demonstrated to improve the median survival time, GBM
still recurs in most patients. Recurrent GBM is still a therapeutic challenge for
clinical physicians. Surgical intervention and other conventional chemoagents have
been applied to manage recurrent GBM. Stereotactic radiosurgery (SRS) provides a
highly precise radiation dose to the tumor lesion and reduces the dose to the
adjacent normal brain tissue. After standard treatment for newly diagnosed GBM is
completed, conventional re-irradiation therapy is not suitable for patients with
recurrent GBMs. Therefore, SRS may become an alternative option in the treatment
of recurrent GBMs. In this review, we discuss the relevant literature regarding SRS
for recurrent GBMs and provide treatment advice for clinical physicians.
Keywords: stereotactic radiosurgery, recurrent glioblastoma multiforme,
re-irradiation, survival time, prognosis
1. Introduction
Glioblastoma multiforme (GBM) is the most common primary brain neoplasm
in adults [1, 2]. There are 1.6 times more males than females who develop a GBM
[1]. According to the latest statistical report of the Central Brain Tumor Registry of
the USA, the annual incidence of GBM has been estimated at approximately 3.22
cases per 100,000 people, and the median age is 65 years [3]. The current standard
treatment of patients with a newly diagnosed GBM was established in 2005, and it
consists of maximal surgical resection of the tumor followed by chemotherapy and
conventional radiotherapy [4, 5]. Despite this therapy, the median overall survival
time is approximately 15–17 months [2].
GBM is a refractory malignant and infiltrating tumor that may recur any time
after initial multimodal treatments are completed [6]. Managing recurrent GBM has
always been challenging, and a balance has to be achieved between significant
treatment toxicity and associated morbidities and mortalities [6, 7]. Reoperation
with maximal resection at recurrence remains as an independent predictor to
improve overall survival [8, 9]. However, repeat gross-total resection may not be
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easily achieved when recurrent GBM involves important eloquent brain structures,
such as the brainstem or motor area. Extensive bevacizumab and temozolomide are
the two main FDA-approved chemoagents used to treat patients with recurrent
GBMs, but the prognosis remains poor [10].
Re-irradiation is an alternative option for managing recurrent GBMs [11]. The
majority of recurrent tumors occur at the initial or adjacent regional sites [12].
Because a total dose of 60 Gy in 30 fractions has been prescribed for initial radiation
therapy, re-irradiation with further dose escalation appears to produce more signif-
icant toxicity [10, 11]. Stereotactic radiosurgery (SRS) is a noninvasive treatment
that provides a highly precise, targeted additional radiation boost to the tumor
lesion, and it maintains an acceptable rate of adverse radiation effects while reduc-
ing the dose to adjacent normal brain tissues [13]. In this review, we searched the
relevant literature and investigated the role of SRS in the management of recurrent
GBMs. Our results may provide treatment information for clinical treatment.
2. Search methodology
In this study, different combinations of the keywords “recurrent glioblastoma
multiple,” “high-grade glioma,” “stereotactic radiosurgery,” and “re-irradiation”were
used to search the published literature in the PubMed database until October 31, 2019.
The inclusion criteria of the study were (1) patients with recurrent GBMs, (2) treat-
ment with stereotactic radiosurgery (SRS) or a fractionated radiosurgery (less than 5
fractions), and (3) outcomes with overall survival time. Tumor progression was also
accepted as a recurrent disease. Potentially relevant studies were identified from the
reference lists of the studies obtained from the database search. Articles excluded from
the review were those written in languages other than English and those that lacked
survival response data. Finally, a total of 49 studies were included in this review.
3. The summary of patients with recurrent GBMs treated with SRS
A total of 49 studies published from 1994 to 2019 were enrolled in this review, as
summarized in Table 1 [13–61]. There were 6 prospective studies and 43 retro-
spective studies. About 2066 patients with recurrent glioblastomas treated with
SRS, including linear accelerator (LINAC) radiosurgery, Gamma Knife radiosur-
gery, and Cyberknife radiosurgery, are reported. In all studies, the median age of
the patients who received SRS treatment for recurrent GBM ranged from 34 to
62 years. The majority of patients were males. The median prescribed dose of SRS
ranged from 6 to 30 Gy. The median targeted volume for treatment ranged from
1.35 to 21.3 cc. The overall survival time from treatment for SRS ranged from 3.9 to
17.9 months, where the progression-free survival time from the treatment of SRS
ranged from 2.1 to 14.9 months. In the prognostic analysis of survival time in
patients with recurrent GBMs treated with SRS, a small tumor volume, younger age,
higher Karnofsky performance scale (KPS) score, lower recursive partitioning
analysis (RPA) class, adjuvant bevacizumab, methylated O6-methylguanine-DNA-
methyltransferase (MGMT) promoter, and longer interval between the original
surgery and SRS were significantly associated with patients’ survival outcomes.
3.1 The effect of LINAC radiosurgery in patients with recurrent GBMs
From 1994 to 2018, a total of 501 patients with recurrent GBMs treated with
LINAC SRS were enrolled in 22 studies, including 3 prospective trials and 17
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Table 1.
Summary of the published literature on stereotactic radiosurgery in patients with recurrent glioblastoma multiforme.
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retrospective studies [14–16, 19, 21, 23–26, 28, 32, 33, 35, 39, 40, 43, 49, 51, 54, 56,
60, 61]. The median age ranged from 34 to 54 years. The median prescribed dose
ranged from 13 to 30 Gy. The median targeted tumor volume was 4.5 to 41.3 cc. The
median overall survival time from the treatment of SRS ranged from 3.9 to
14.4 months, whereas the median progression-free survival time was 2.1 to
11 months.
The first study about LINAC radiosurgery for recurrent GBMs was described by
Chamerian et al. [14]. The median prescribed dose was 13.4 Gy, and the median
treated tumor volume was 17 cc. The median overall survival time was only
8 months, whereas the median progression-free survival time was 4 months. After
that, only one retrospective study of more than 100 patients with recurrent high-
grade gliomas treated with LINAC SRS has been reported [16]. Shrieve et al. showed
that the median survival time of 72 recurrent GBM patients was 10.2 months [16].
Younger age (less than 46 years) and small tumor volume (less than 10.1 cc) were
the significant prognostic factors associated with survival time. There were two
studies that enrolled patients with only recurrent GBMs [21, 33]. In 2005, Combs
et al. reported 32 patients, including 19 males and 13 females with recurrent GBMs
treated with LINAC SRS [21]. The median age was 56 years, ranging from 33 to
76 years. The median prescribed radiation dose was 15 Gy, ranging from 10 to
20 Gy. The median targeted tumor volume was 10 cc with a range of 1.2 to 59.2 cc.
The median overall survival time and progression-free survival time were 10 and
5 months, respectively. However, no prognostic factor was significant enough to
influence the survival time. In a retrospective study of 19 patients with recurrent
GBMs, Sirin et al. also showed that the median overall survival time and
progression-free survival time were only 9.3 and 5.7 months, respectively [33]. In
the bevacizumab era, three studies reported the combination of LINAC SRS, and
bevacizumab improved the overall survival time ranging from 11.2 to 14.4 months
[35, 39, 40]. In a retrospective study of 48 patients with recurrent GBMs, Cuneo
et al. reported that the median progression-free survival time in recurrent patients
who received adjuvant bevacizumab and LINAC SRS was 5.2 months vs. 2.1 months
for patients who received LINAC SRS alone. The median overall survival times for
patients who received a combination of adjuvant bevacizumab/LINAC SRS and
LINAC SRS alone were 11.2 and 3.9 months, respectively. The authors concluded
that the combination of salvage radiosurgery and bevacizumab to treat recurrent
malignant gliomas seemed to be associated with improved outcomes. Younger age
and higher KPS were still significant prognostic factors associated with overall
survival time in patients with recurrent GBMs.
3.2 The effect of gamma knife radiosurgery in patients with recurrent GBMs
From 1996 to 2019, a total of 1247 patients with recurrent GBMs in 23 published
studies were treated with Gamma Knife SRS [13, 17, 18, 20, 22, 24, 27, 29, 31, 36–
38, 41, 45, 47, 50, 52, 53, 55, 57–59, 61]. The median age ranged from 43 to 61 years.
The median prescribed marginal dose varied from 6 to 20 Gy. The median targeted
tumor volume ranged from 1.35 to 21.4 cc. The median overall survival time ranged
from 7 to 30 months, whereas the median progression-free survival time ranged
from 3.8 to 14.9 months.
In a retrospective study of 189 patients with recurrent high-grade gliomas
treated with Gamma Knife SRS, Larson et al. first reported that the median overall
survival time in 66 patients with recurrent GBMs was 10 months [17]. Younger age,
smaller tumor volume, higher KPS, and unifocal tumors were significant prognostic
factors associated with patients’ overall survival times. Several studies reported the
impact of a combination of Gamma Knife SRS and adjuvant chemoagents on overall
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survival times [17, 37, 47, 55, 59]. In 2002, Larson et al. reported a prospective phase
II study on patients who received a combination of Gamma Knife SRS, and
marimastat had a median overall survival of 8.7 months, whereas the median sur-
vival time in patients who received only Gamma Knife SRS alone was 10.1 months.
Marimastat did not offer an advantage for patients with recurrent GBMs. However,
in a retrospective study of 57 patients with recurrent GBMs, Kim et al. showed that
the combination of adjuvant temozolomide and Gamma Knife SRS significantly
improved the medium overall survival time from 9.2 to 15.5 months [47]. In the
bevacizumab era, two studies reported that the median survival time was approxi-
mately 13 months after the combined treatment of Gamma Knife SRS and adjuvant
bevacizumab [55, 59].
3.3 The effect of Cyberknife radiosurgery in patients with recurrent GBMs
From 2009 to 2017, a total of 318 patients with recurrent GBMs in eight published
studies were treated with Cyberknife SRS [30, 34, 42, 44, 46, 48, 51, 54]. The median
age ranged from 37 to 59.9 years. The median prescribed marginal dose ranged from
15 to 30 Gy. The median targeted tumor volume ranged from 2 to 24 cc. The median
overall survival time after Cyberknife SRS ranged from 5.3 to 12 months, whereas the
median progression-free survival time ranged from 4 to 7.9 months.
The first report on Cyberknife SRS for patients with recurrent GBMs was
published by Villavicencio et al. [30]. The median overall survival time in a total of
26 patients with recurrent GBMs was 7 months. No prognostic factor associated
with the overall survival time was identified. In 2015, Pinzi et al. reported a retro-
spective study of more than 100 patients who had recurrent high-grade glioma
treated with Cyberknife SRS [48]. Among 88 patients with recurrent GBMs, the
median survival time was 10 months after treatment with Cyberknife SRS. Adju-
vant second-line chemotherapy and/or surgery were the significant prognostic fac-
tors associated with overall survival times. The effect of adjuvant chemoagents,
including bevacizumab, temozolomide, and anti-epidermal factor (125)-mAB 425,
on the overall survival times was evaluated in four studies [34, 42, 44, 46]. In 2012,
Conti et al. compared the effect of a combination of temozolomide and Cyberknife
SRS with that of Cyberknife SRS alone on the overall survival times of patients with
recurrent GBMs [34]. The progression-free survival time and median survival time
in patients who received the adjuvant temozolomide and Cyberknife SRS were 7
and 12 months, respectively. The patients who received Cyberknife SRS alone had a
progression-free survival time and median survival time of only 4 and 7 months,
respectively. In the bevacizumab era, Yazici et al. revealed that the median survival
time in 37 patients with recurrent GBMs was 10.6 months, whereas the median
progression-free survival time was 7.9 months [44]. A tumor volume less than 24 cc
was the only significant prognostic factor associated with overall survival times.
4. Discussion
4.1 The role of SRS for recurrent GBMs
GBM is an incurable disease with local progression in the majority of patients.
The management of recurrent GBMs is a clinically challenging problem, and treat-
ment options are limited [7, 10]. Although reoperation with gross-total removal of
the tumor has been shown to improve the overall survival time in patients with
recurrent GBMs, surgery may not be preferred for patients with tumors in the
eloquent area, older age, or lower performance status [8]. Re-irradiation offers an
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alternative option for treating recurrent GBMs. In a systematic review and meta-
analysis of re-irradiation with external beam radiotherapy for recurrent GBMs,
Kazmi et al. showed that the 6- and 12-month overall survival times from the time
of re-irradiation were 70 and 34%, respectively, whereas the 6- and 12-month
progression-free survival times were 40 and 16%, respectively [11]. The overall
toxicity rate was low, ranging from 4 to 10%.
SRS has the ability to combine surgical and radio-oncological treatments to
deliver a high dose of focused radiation on the focal tumor lesion and spare the
adjacent normal anatomical structures. For recurrent GBMs, the majority of tumors
tend to grow within 2 cm of the contrast-enhancing lesion border, and SRS seems to
be a reasonable tool to add radiation boost for the focal lesion followed by the
standard treatment of initial radiation with 60 Gy in 30 fractions [4, 13]. In our
present review, despite the different SRS modalities with the median prescribed
dose ranging from 6 to 30 Gy, the overall survival time from the treatment of SRS
ranged from 3.9 to 17.9 months, where the progression-free survival time from the
treatment of SRS ranged from 2.1 to 14.9 months. Severe prognostic factors, such as
small tumor volume, younger age, higher KPS score, and lower RPA class, were
mostly suggested to be significantly associated with the overall survival time in
patients with recurrent GBMs treated with SRS. These results showed that re-
irradiation with the SRS modality are an alternative and feasible method to manage
patients with recurrent GBMs.
4.2 The impact of SRS and adjuvant temozolomide for recurrent GBMs
Since 2005, temozolomide, which is an alkylating agent, is the most important
FDA-approved chemoagent for the standard treatment of patients with newly diag-
nosed GBMs [1, 4]. The median overall survival time significantly improved from
12.1 to 14.6 months after the patients with newly diagnosed GBMs received combined
treatments with radiotherapy and adjuvant temozolomide. However, the disease
frequently progresses within 6–9 months, and the 2-year survival rate is less than 25%
[62]. The failure of temozolomide treatment has been found to be associated with the
expression of MGMT protein [63–65]. Among the GBM patients with a methylated
MGMT promoter, the median overall survival time was 21.7 months after treatment
with radiotherapy and temozolomide, whereas the median survival time was
15.3 months in the unmethylated group treated with radiotherapy alone [64].
Due to the blood-brain barrier, temozolomide rechallenge is considered to be a
reasonable option in patients with recurrent GBMs. In this review, the combination
of SRS and temozolomide was employed in three studies [34, 42, 47]. Cyberknife
SRS was performed in two studies, and the other study used the Gamma Knife SRS.
The median overall survival time ranged from 9 to 15.5 months, and the median
progression-free survival time was approximately 7 months after the time of SRS
treatment. In 2012, Conti et al. analyzed the effect of adjuvant temozolomide in
recurrent GBM patients treated with Cyberknife SRS [34]. The median overall
survival time significantly improved from 7 to 12 months, whereas the median
progression-free survival time improved from 4 to 7 months. Based on 57 recurrent
GBM patients, Kim et al. also showed that the improved median overall survival
time and progression-free survival time were 15.5 and 6 months, respectively [47].
Otherwise, in a retrospective review of 61 patients who received Gamma Knife SRS
as a salvage treatment at the time of the first progression, Kim et al. showed that the
median overall survival time was 14 months in the methylated MGMT promoter
group and 9 months in the unmethylated group [53]. Methylation of the MGMT
promoter was significantly corrected with better overall survival times and
progression-free survival times. The results mentioned above indicated that the
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combination of salvage SRS and adjuvant temozolomide may offer an important
treatment option to improve the overall survival times in patients with recurrent
GBMs.
4.3 The impact of SRS and adjuvant bevacizumab for recurrent GBMs
Bevacizumab is a recombinant human monoclonal antibody that acts against the
vascular endothelial growth factor to prevent the growth and maintenance of tumor
blood vessels. In 2009, bevacizumab was approved by the USFDA for the treatment
of patients with recurrent GBMs [66, 67]. The use of bevacizumab demonstrated a
radiological response of up to 40% [68]. However, in a large prospective phase III
trial, the use of adjuvant bevacizumab revealed only improvement in the
progression-free survival times from 1.5 to 4.2 months but not in the overall sur-
vival times [69]. In a systematic review and meta-analysis, Diaz et al. showed that
the survival advantage of bevacizumab at recurrence was limited to 4 months [70].
Although bevacizumab may reduce steroid requirements, there was no additional
benefit in the health-related quality of life. The role of bevacizumab in combination
with other cytotoxic chemoagents remains unclear.
The role of adjuvant bevacizumab in patients with recurrent GBMs treated with
SRS has been reported in nine studies, which were included in our review [35, 37,
39, 40, 44, 46, 49, 55, 59]. The median overall survival time ranged from 5.3 to
17.9 months, whereas the median progression-free survival time ranged from 3.9 to
14.9 months. The comparison of SRA with or without adjuvant bevacizumab was
investigated in two studies [35, 37]. Among 49 patients with recurrent GBMs,
Cuneo et al. showed that the median overall survival time was 11.2 months in
patients receiving SRS and adjuvant bevacizumab and 3.9 months in patients
receiving SRS therapy alone [35]. The progression-free survival time also improved
from 2.1 to 5.2 months. In a case-controlled study of patients with recurrent GBMs
treated with SRS and adjuvant bevacizumab plus temozolomide or irinotecan, Park
et al. also showed that the median overall survival time and progression-free sur-
vival time improved from 12.2 to 17.9 months and 6.7 to 14.9 months, respectively
[37]. In a retrospective study and review of the literature, Morris et al. reported that
the dual role of bevacizumab and radiosurgery had a benefit in the overall survival
times (11.2–17.9 months) and progression-free survival times (3.9–14.9 months).
These results showed the potential therapeutic effect of adjuvant bevacizumab in
combination with other treatment modalities, such as cytotoxic chemoagents or
salvage SRS, in patients with recurrent GBMs.
4.4 The future of SRS for recurrent GBMs
With the advance of molecular diagnostic techniques, newly diagnosed GBMs
should be classified based on the mutant status of isocitrate dehydrogenase 1
defined by the updated guidelines of the World Health Organization in 2016 [71].
These molecular profiles influence the overall survival time and the possible thera-
peutic effects of chemoagents. Similar to the recurrent GBMs, several main mole-
cules, such as MLH1 [72], CASP8 [73], MSH2 [74], and P53 [74], were found to be
different from primary GBMs [75]. The molecular features, intra-tumor heteroge-
neity, immunogenicity, and microenvironment around the tumor contribute to the
clinical prognostic outcomes in patients with recurrent GBMs [7, 10]. Reoperation,
re-chemotherapy, and re-irradiation currently remain as the standard treatments
for most patients with recurrent GBMs [2, 7, 10, 11]. A growing body of literature,
including our current review, demonstrates the tolerability and efficacy of salvage
SRS for recurrent GBMs, which did not inhibit re-irradiation, followed by a total of
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60 Gy typically applied in the first-line treatment [59]. Although younger age is
commonly considered as an important independent prognostic factor that is associ-
ated with survival, the selected criteria of salvage SRS for better outcomes need to
be investigated in further large prospective studies. In the future, individualized
precise multi-modality treatment will play an important role in patients with
recurrent GBMs, including the combination of cytotoxic chemotherapy, angiogen-
esis inhibitors, or immunotherapy [76]. Salvage SRS with a combination of other
treatment modalities may offer an alternative therapeutic method to manage
patients with recurrent GBMs.
5. Conclusion
Our review suggests that salvage SRS is an important treatment protocol for
managing patients with recurrent GBMs. The irradiation doses provided by SRS
may improve the clinical outcome of patients with recurrent GBMs, which is not
hampered by the standard case of 60 Gy prescribed for newly diagnosed GBMs. The
dual role of salvage SRS and other cytotoxic chemoagents, such as temozolomide
and bevacizumab, also seems to be effective in the management of recurrent GBMs.
Further application of salvage SRS combined with other chemoagents or a new
treatment modality needs to be investigated.
Conflict of interest
The authors declare no conflict of interest.
Author details
Cheng-Ta Hsieh1,2,3 and Da-Tong Ju3*
1 Division of Neurosurgery, Department of Surgery, Sijhih Cathay General
Hospital, New Taipei City, Taiwan
2 Department of Medicine, School of Medicine, Fu Jen Catholic University,
New Taipei City, Taiwan
3 Department of Neurological Surgery, Tri-Service General Hospital, National
Defense Medical Center, Taipei City, Taiwan
*Address all correspondence to: wxyz670628@yahoo.com.tw
©2020TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
11
Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme
DOI: http://dx.doi.org/10.5772/intechopen.91163
References
[1] Preusser M, de Ribaupierre S,
Wöhrer A, Erridge SC, Hegi M,
Weller M, et al. Current concepts and
management of glioblastoma. Annals of
Neurology. 2011;70(1):9-21
[2]Weller M, Cloughesy T, Perry JR,
Wick W. Standards of care for
treatment of recurrent glioblastoma—
Are we there yet? Neuro-Oncology.
2013;15(1):4-27
[3]Ostrom QT, Cioffi G, Gittleman H,
Patil N, Waite K, Kruchko C, et al.
CBTRUS statistical report: Primary
brain and other central nervous system
tumors diagnosed in the United States in
2012–2016. Neuro-Oncology. 2019;21
(Suppl. 5):v1-v100
[4] Stupp R,MasonWP, van den BentMJ,
Weller M, Fisher B, TaphoornMJ, et al.
Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.
The New England Journal of Medicine.
2005;352(10):987-996
[5] Sanai N, Polley MY, McDermott MW,
Parsa AT, Berger MS. An extent of
resection threshold for newly diagnosed
glioblastomas. Journal of Neurosurgery.
2011;115(1):3-8
[6]Hou LC, Veeravagu A, Hsu AR,
Tse VC. Recurrent glioblastoma
multiforme: A review of natural history
and management options. Neurosurgical
Focus. 2006;20(4):E5
[7]Mallick S, Benson R, Hakim A,
Rath GK. Management of glioblastoma
after recurrence: A changing paradigm.
Journal of the Egyptian National Cancer
Institute. 2016;28(4):199-210
[8] Bloch O, Han SJ, Cha S, Sun MZ,
Aghi MK, McDermott MW, et al.
Impact of extent of resection for
recurrent glioblastoma on overall
survival: Clinical article. Journal of
Neurosurgery. 2012;117(6):1032-1038
[9] Lu VM, Goyal A, Graffeo CS,
Perry A, Burns TC, Parney IF, et al.
Survival benefit of maximal resection
for glioblastoma reoperation in the
temozolomide era: A meta-analysis.
World Neurosurgery. 2019;127:31-37
[10]Chaul-Barbosa C, Marques DF. How
we treat recurrent glioblastoma today
and current evidence. Current Oncology
Reports. 2019;21(10):94
[11] Kazmi F, Soon YY, Leong YH,
Koh WY, Vellayappan B. Re-irradiation
for recurrent glioblastoma (GBM): A
systematic review and meta-analysis.
Journal of Neuro-Oncology. 2019;
142(1):79-90
[12] Jayamanne D, Wheeler H,
Brazier D, Newey A, Kastelan M, Guo L,
et al. Predicting patterns of failure in
temporal lobe GBMs: Possible
implications on radiotherapy treatment
portals. Radiotherapy and Oncology.
2018;13(1):133
[13]Niranjan A, Kano H, Iyer A,
Kondziolka D, Flickinger JC,
Lunsford LD. Role of adjuvant or
salvage radiosurgery in the management
of unresected residual or progressive
glioblastoma multiforme in the
pre-bevacizumab era. Journal of
Neurosurgery. 2015;122(4):757-765
[14] Chamberlain MC, Barba D,
Kormanik P, Shea WM. Stereotactic
radiosurgery for recurrent gliomas.
Cancer. 1994;74(4):1342-1347
[15]Hall WA, Djalilian HR,
Sperduto PW, Cho KH, Gerbi BJ,
Gibbons JP, et al. Stereotactic
radiosurgery for recurrent malignant
gliomas. Journal of Clinical Oncology.
1995;13(7):1642-1648
[16] Shrieve DC, Alexander E 3rd,
Wen PY, Fine HA, Kooy HM, Black PM,
et al. Comparison of stereotactic
12
Tumor Progression and Metastasis
radiosurgery and brachytherapy in the
treatment of recurrent glioblastoma
multiforme. Neurosurgery. 1995;36(2):
275-282 discussion 82-4
[17] Larson DA, Gutin PH,
McDermott M, Lamborn K, Sneed PK,
Wara WM, et al. Gamma knife for
glioma: Selection factors and survival.
International Journal of Radiation
Oncology, Biology, Physics. 1996;36(5):
1045-1053
[18] Kondziolka D, Flickinger JC,
Bissonette DJ, Bozik M, Lunsford LD.
Survival benefit of stereotactic
radiosurgery for patients with
malignant glial neoplasms.
Neurosurgery. 1997;41(4):776-783
discussion 83-5
[19] Cho KH, Hall WA, Gerbi BJ,
Higgins PD, McGuire WA, Clark HB.
Single dose versus fractionated
stereotactic radiotherapy for recurrent
high-grade gliomas. International
Journal of Radiation Oncology, Biology,
Physics. 1999;45(5):1133-1141
[20] Larson DA, Prados M, Lamborn KR,
Smith V, Sneed PK, Chang S, et al. Phase
II study of high central dose Gamma
knife radiosurgery and marimastat in
patients with recurrent malignant
glioma. International Journal of
Radiation Oncology, Biology, Physics.
2002;54(5):1397-1404
[21] Combs SE, Widmer V, Thilmann C,
Hof H, Debus J, Schulz-Ertner D.
Stereotactic radiosurgery (SRS):
Treatment option for recurrent
glioblastoma multiforme (GBM).
Cancer. 2005;104(10):2168-2173
[22]Hsieh PC, Chandler JP, Bhangoo S,
Panagiotopoulos K, Kalapurakal JA,
Marymont MH, et al. Adjuvant gamma
knife stereotactic radiosurgery at the
time of tumor progression potentially
improves survival for patients with
glioblastoma multiforme. Neurosurgery.
2005;57(4):684-692 discussion 684
[23]Mahajan A, McCutcheon IE, Suki D,
Chang EL, Hassenbusch SJ,
Weinberg JS, et al. Case-control study of
stereotactic radiosurgery for recurrent
glioblastoma multiforme. Journal of
Neurosurgery. 2005;103(2):210-217
[24] Kong DS, Lee JI, Park K, Kim JH,
Lim DH, Nam DH. Efficacy of
stereotactic radiosurgery as a salvage
treatment for recurrent malignant
gliomas. Cancer. 2008;112(9):2046-2051
[25] Schwer AL, Damek DM,
Kavanagh BD, Gaspar LE, Lillehei K,
Stuhr K, et al. A phase I dose-escalation
study of fractionated stereotactic
radiosurgery in combination with
gefitinib in patients with recurrent
malignant gliomas. International Journal
of Radiation Oncology, Biology, Physics.
2008;70(4):993-1001
[26] Biswas T, Okunieff P, Schell MC,
Smudzin T, Pilcher WH, Bakos RS, et al.
Stereotactic radiosurgery for
glioblastoma: Retrospective analysis.
Radiotherapy and Oncology. 2009;4:11
[27] Kida Y, Yoshimoto M, Hasegawa T.
Radiosurgery for intracranial gliomas.
Progress in Neurological Surgery. 2009;
22:122-128
[28] Patel M, Siddiqui F, Jin JY,
Mikkelsen T, Rosenblum M, Movsas B,
et al. Salvage reirradiation for recurrent
glioblastoma with radiosurgery:
Radiographic response and improved
survival. Journal of Neuro-Oncology.
2009;92(2):185-191
[29] Pouratian N, Crowley RW,
Sherman JH, Jagannathan J, Sheehan JP.
Gamma knife radiosurgery after
radiation therapy as an adjunctive
treatment for glioblastoma. Journal of
Neuro-Oncology. 2009;94(3):409-418
[30] Villavicencio AT, Burneikiene S,
Romanelli P, Fariselli L, McNeely L,
Lipani JD, et al. Survival following
stereotactic radiosurgery for newly
13
Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme
DOI: http://dx.doi.org/10.5772/intechopen.91163
diagnosed and recurrent glioblastoma
multiforme: A multicenter experience.
Neurosurgical Review. 2009;32(4):
417-424
[31] Elliott RE, Parker EC, Rush SC,
Kalhorn SP, Moshel YA, Narayana A,
et al. Efficacy of gamma knife
radiosurgery for small-volume recurrent
malignant gliomas after initial radical
resection. World Neurosurgery. 2011;76
(1–2):128-140 discussion 61-2
[32]Maranzano E, Anselmo P, Casale M,
Trippa F, Carletti S, Principi M, et al.
Treatment of recurrent glioblastoma
with stereotactic radiotherapy: Long-
term results of a mono-institutional
trial. Tumori. 2011;97(1):56-61
[33] Sirin S, Oysul K, Surenkok S,
Sager O, Dincoglan F, Dirican B, et al.
Linear accelerator-based stereotactic
radiosurgery in recurrent glioblastoma:
A single center experience.
Vojnosanitetski Pregled. 2011;68(11):
961-966
[34] Conti A, Pontoriero A, Arpa D,
Siragusa C, Tomasello C, Romanelli P,
et al. Efficacy and toxicity of Cyberknife
re-irradiation and “dose dense”
temozolomide for recurrent gliomas.
Acta Neurochirurgica. 2012;154(2):
203-209
[35] Cuneo KC, Vredenburgh JJ,
Sampson JH, Reardon DA, Desjardins A,
Peters KB, et al. Safety and efficacy of
stereotactic radiosurgery and adjuvant
bevacizumab in patients with recurrent
malignant gliomas. International Journal
of Radiation Oncology, Biology, Physics.
2012;82(5):2018-2024
[36] Koga T, Maruyama K, Tanaka M,
Ino Y, Saito N, Nakagawa K, et al.
Extended field stereotactic radiosurgery
for recurrent glioblastoma. Cancer.
2012;118(17):4193-4200
[37] Park KJ, Kano H, Iyer A, Liu X,
Niranjan A, Flickinger JC, et al. Salvage
gamma knife stereotactic radiosurgery
followed by bevacizumab for recurrent
glioblastoma multiforme: A case-control
study. Journal of Neuro-Oncology. 2012;
107(2):323-333
[38] Skeie BS, Enger PØ, Brøgger J,
Ganz JC, Thorsen F, Heggdal JI, et al.
Gamma knife surgery versus
reoperation for recurrent glioblastoma
multiforme. World Neurosurgery. 2012;
78(6):658-669
[39] Cabrera AR, Cuneo KC,
Desjardins A, Sampson JH, McSherry F,
Herndon JE 2nd, et al. Concurrent
stereotactic radiosurgery and
bevacizumab in recurrent malignant
gliomas: A prospective trial.
International Journal of Radiation
Oncology, Biology, Physics. 2013;86(5):
873-879
[40] Clark GM, McDonald AM,
Nabors LB, Fathalla-Shaykh H, Han X,
Willey CD, et al. Hypofractionated
stereotactic radiosurgery with
concurrent bevacizumab for recurrent
malignant gliomas: The University of
Alabama at Birmingham experience.
Neurooncology Practice. 2014;1(4):
172-177
[41]Dodoo E, Huffmann B, Peredo I,
Grinaker H, Sinclair G, Machinis T,
et al. Increased survival using delayed
gamma knife radiosurgery for recurrent
high-grade glioma: A feasibility study.
World Neurosurgery. 2014;82(5):e623-
e632
[42]Greenspoon JN, Sharieff W,
Hirte H, Overholt A, Devillers R,
Gunnarsson T, et al. Fractionated
stereotactic radiosurgery with
concurrent temozolomide
chemotherapy for locally recurrent
glioblastoma multiforme: A prospective
cohort study. OncoTargets and Therapy.
2014;7:485-490
[43]Martínez-Carrillo M, Tovar-
Martín I, Zurita-Herrera M, Del Moral-
14
Tumor Progression and Metastasis
Ávila R, Guerrero-Tejada R, Saura-Rojas
E, et al. Salvage radiosurgery for
selected patients with recurrent
malignant gliomas. BioMed Research
International. 2014;2014:657953
[44] Yazici G, Cengiz M, Ozyigit G,
Eren G, Yildiz F, Akyol F, et al.
Hypofractionated stereotactic
reirradiation for recurrent glioblastoma.
Journal of Neuro-Oncology. 2014;
120(1):117-123
[45] Bir SC, Connor DE Jr, Ambekar S,
Wilden JA, Nanda A. Factors predictive
of improved overall survival following
stereotactic radiosurgery for recurrent
glioblastoma. Neurosurgical Review.
2015;38(4):705-713
[46]Hasan S, Chen E, Lanciano R,
Yang J, Hanlon A, Lamond J, et al.
Salvage fractionated stereotactic
radiotherapy with or without
chemotherapy and immunotherapy for
recurrent glioblastoma multiforme: A
single institution experience. Frontiers
in Oncology. 2015;5:106
[47] Kim HR, Kim KH, Kong DS,
Seol HJ, Nam DH, Lim DH, et al.
Outcome of salvage treatment for
recurrent glioblastoma. Journal of
Clinical Neuroscience. 2015;22(3):
468-473
[48] Pinzi V, Orsi C, Marchetti M,
Milanesi IM, Bianchi LC, DiMeco F,
et al. Radiosurgery reirradiation for
high-grade glioma recurrence: A
retrospective analysis. Neurological
Sciences. 2015;36(8):1431-1440
[49] Bokstein F, Blumenthal DT,
Corn BW, Gez E, Matceyevsky D,
Shtraus N, et al. Stereotactic radiosurgery
(SRS) in high-grade glioma: Judicious
selection of small target volumes
improves results. Journal of Neuro-
Oncology. 2016;126(3):551-557
[50] Frischer JM, Marosi C, Woehrer A,
Hainfellner JA, Dieckmann KU, Eiter H,
et al. Gamma knife radiosurgery in
recurrent glioblastoma. Stereotactic and
Functional Neurosurgery. 2016;94(4):
265-272
[51]Holt DE, Bernard ME, Quan K,
Clump DA, Engh JA, Burton SA, et al.
Salvage stereotactic radiosurgery for
recurrent glioblastoma multiforme with
prior radiation therapy. Journal of
Cancer Research and Therapeutics.
2016;12(4):1243-1248
[52] Imber BS, Kanungo I, Braunstein S,
Barani IJ, Fogh SE, Nakamura JL, et al.
Indications and efficacy of gamma knife
stereotactic radiosurgery for recurrent
glioblastoma: 2 decades of institutional
experience. Neurosurgery. 2017;80(1):
129-139
[53]Kim BS, Kong DS, Seol HJ, Nam DH,
Lee JI. MGMT promoter methylation
status as a prognostic factor for the
outcome of gamma knife radiosurgery
for recurrent glioblastoma. Journal of
Neuro-Oncology. 2017;133(3):615-622
[54] Sutera PA, Bernard ME, Gill BS,
Quan K, Engh JA, Burton SA, et al.
Salvage stereotactic radiosurgery for
recurrent gliomas with prior radiation
therapy. Future Oncology. 2017;13(29):
2681-2690
[55] Abbassy M, Missios S, Barnett GH,
Brewer C, Peereboom DM,
Ahluwalia M, et al. Phase I trial of
radiosurgery dose escalation plus
bevacizumab in patients with recurrent/
progressive glioblastoma. Neurosurgery.
2018;83(3):385-392
[56] Gigliotti MJ, Hasan S, Karlovits SM,
Ranjan T, Wegner RE. Re-irradiation
with stereotactic radiosurgery/
radiotherapy for recurrent high-grade
gliomas: Improved survival in the
modern era. Stereotactic and Functional
Neurosurgery. 2018;96(5):289-295
[57]Guseynova K, Liscak R,
Simonova G, Novotny J Jr. Gamma knife
15
Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme
DOI: http://dx.doi.org/10.5772/intechopen.91163
radiosurgery for local recurrence of
glioblastoma. Neuro Endocrinology
Letters. 2018;39(4):281-287
[58] Sharma M, Schroeder JL, Elson P,
Meola A, Barnett GH, Vogelbaum MA,
et al. Outcomes and prognostic
stratification of patients with recurrent
glioblastoma treated with salvage
stereotactic radiosurgery. Journal of
Neurosurgery. 2018:1-11
[59]Morris SL, Zhu P, Rao M, Martir M,
Zhu JJ, Hsu S, et al. Gamma knife
stereotactic radiosurgery in combination
with bevacizumab for recurrent
glioblastoma. World Neurosurgery.
2019;127:e523-e533
[60] Sanghavi S, Skrupky R, Badie B,
Robins I, Tome W, Mehta MP.
Recurrent malignant gliomas treated
with radiosurgery. Journal of
Radiosurgery. 1999;2(3):119-125
[61] Park JL, Suh JH, Barnett GH,
Reddy CA, Peereboom DM,
Stevens GHJ, et al. Survival after
stereotactic radiosurgery for recurrent
glioblastoma multiforme. Journal of
Radiosurgery. 2000;3(4):169-175
[62]Wen PY, Kesari S. Malignant
gliomas in adults. The New England
Journal of Medicine. 2008;359(5):
492-507
[63] Silber JR, Bobola MS, Blank A,
Chamberlain MC. O6-methylguanine-
DNA methyltransferase in glioma
therapy: Promise and problems.
Biochimica et Biophysica Acta. 2012;
1826(1):71-82
[64]Hegi ME, Diserens AC, Gorlia T,
Hamou MF, de Tribolet N, Weller M,
et al. MGMT gene silencing and benefit
from temozolomide in glioblastoma.
The New England Journal of Medicine.
2005;352(10):997-1003
[65]Hsieh CT, Su IC, Huang CT,
Chang CJ, Wang JS. The prognostic
value of O6-methylguanine-DNA
methyltransferase gene promoter
methylation detected by gel-based
methylation-specific polymerase chain
reaction in patients with glioblastoma
multiforme: A systematic review.
International Journal of Clinical and
Experimental Medicine. 2016;9(6):
10899-10906
[66] Kreisl TN, Kim L, Moore K, Duic P,
Royce C, Stroud I, et al. Phase II trial of
single-agent bevacizumab followed by
bevacizumab plus irinotecan at tumor
progression in recurrent glioblastoma.
Journal of Clinical Oncology. 2009;
27(5):740-745
[67] Friedman HS, Prados MD, Wen PY,
Mikkelsen T, Schiff D, Abrey LE, et al.
Bevacizumab alone and in combination
with irinotecan in recurrent
glioblastoma. Journal of Clinical
Oncology. 2009;27(28):4733-4740
[68] Chinot OL, Wick W, Mason W,
Henriksson R, Saran F, Nishikawa R,
et al. Bevacizumab plus radiotherapy-
temozolomide for newly diagnosed
glioblastoma. The New England Journal
of Medicine. 2014;370(8):709-722
[69]Wick W, Gorlia T, Bendszus M,
Taphoorn M, Sahm F, Harting I, et al.
Lomustine and bevacizumab in
progressive glioblastoma. The New
England Journal of Medicine. 2017;
377(20):1954-1963
[70]Diaz RJ, Ali S, Qadir MG, De La
Fuente MI, Ivan ME, Komotar RJ. The
role of bevacizumab in the treatment of
glioblastoma. Journal of Neuro-
Oncology. 2017;133(3):455-467
[71] Louis DN, Perry A, Reifenberger G,
von Deimling A, Figarella-Branger D,
Cavenee WK, et al. The 2016 World
Health Organization classification of
tumors of the central nervous system: A
summary. Acta Neuropathologica. 2016;
131(6):803-820
16
Tumor Progression and Metastasis
[72] Stark AM, Doukas A, Hugo HH,
Mehdorn HM. The expression of
mismatch repair proteins MLH1, MSH2
and MSH6 correlates with the Ki67
proliferation index and survival in
patients with recurrent glioblastoma.
Neurological Research. 2010;32(8):
816-820
[73]Martinez R, Setien F, Voelter C,
Casado S, Quesada MP, Schackert G,
et al. CpG island promoter
hypermethylation of the pro-apoptotic
gene caspase-8 is a common hallmark of
relapsed glioblastoma multiforme.
Carcinogenesis. 2007;28(6):1264-1268
[74] Stark AM, Witzel P, Strege RJ,
Hugo HH, Mehdorn HM. p53, mdm2,
EGFR, and msh2 expression in paired
initial and recurrent glioblastoma
multiforme. Journal of Neurology,
Neurosurgery, and Psychiatry. 2003;
74(6):779-783
[75] Campos B, Olsen LR, Urup T,
Poulsen HS. A comprehensive profile of
recurrent glioblastoma. Oncogene. 2016;
35(45):5819-5825
[76] Seystahl K, Gramatzki D, Roth P,
Weller M. Pharmacotherapies for the
treatment of glioblastoma—Current
evidence and perspectives. Expert
Opinion on Pharmacotherapy. 2016;
17(9):1259-1270
17
Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme
DOI: http://dx.doi.org/10.5772/intechopen.91163
